Arvinas Inc ARVN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $7.74
- Day Range
- $7.40–7.81
- 52-Week Range
- $6.06–14.51
- Bid/Ask
- $7.19 / $7.35
- Shares Outstanding
- 64.52M
- Market Cap
- $478.75M
- Volume/Avg
- 649,965 / 880,417
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 5.71
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- 19.20%
Company Profile
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 246
- Website
- https://www.arvinas.com
Valuation
|
Metric
|
ARVN
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.24 |
Price/Sales | 5.71 |
Price/Cash Flow | — |
Price/Earnings
ARVN
Financial Strength
|
Metric
|
ARVN
|
|---|---|
Quick Ratio | 5.36 |
Current Ratio | 5.44 |
Interest Coverage | — |
Quick Ratio
ARVN
Profitability
|
Metric
|
ARVN
|
|---|---|
Return on Assets (Normalized) | −22.92% |
Return on Equity (Normalized) | −35.57% |
Return on Invested Capital (Normalized) | −39.79% |
Return on Assets
ARVN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Cqpnypjwv | Srbyf | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Hymjrkhc | Yqtnr | $67B | |||
| argenx SE ADR
ARGX
| Wvgdjnmy | Bryx | $55B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Yjdxcfb | Rlhlxc | $40B | |||
| Royalty Pharma PLC Class A
RPRX
| Rzddmlzr | Jkdkf | $25B | |||
| BioNTech SE ADR
BNTX
| Szkzfktx | Wvnz | $22B | |||
| Incyte Corp
INCY
| Kqqjxzw | Qsy | $20B | |||
| Moderna Inc
MRNA
| Wptwyycc | Ncwl | $19B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Vnpptgg | Mbdq | $15B | |||
| BridgeBio Pharma Inc
BBIO
| Ncsrgvjw | Txklt | $13B |
United States